Diabetes is associated with endothelial dysfunction, which in part may be related to uncoupling of the endothelial nitric oxide (NO) synthase enzyme, thus reducing the availability of NO. As folates may potentially reverse the uncoupling of NO synthase, we wanted to determine whether folic acid supplementation could modulate endothelial function and markers of inflammation in patients with type 2 diabetes without vascular disease. Nineteen patients with type 2 diabetes were treated with folic acid (10 mg/day for 2 weeks) versus placebo in a randomized, placebo-controlled, cross-over study with an 8-week washout period between treatments. Fasting endothelium-dependent flow-mediated dilatation (FMD) of the brachial artery, endothelium-independent nitroglycerin-mediated dilatation (NMD), plasma homocysteine, serum lipids, folate, and inflammatory markers (high-sensitivity C-reactive protein, soluble intercellular adhesion molecule-1 and vascular cell adhesion molecule-1, interleukin-18, tumor necrosis factor-alpha) were assessed after each 2-week treatment period. Folic acid supplementation significantly increased folate levels and lowered plasma homocysteine levels. Folic acid significantly improved FMD compared to placebo (5.8 Ϯ 4.8% vs 3.2 Ϯ 2.7%, p ϭ 0.02). There were no significant effects of folic acid supplementation on lipids, NMD, or the inflammatory markers. There was no relationship between the change in homocysteine and the improvement in FMD. Thus, 2 weeks of folic acid supplementation can improve endothelial dysfunction in type 2 diabetics independent of homocysteinelowering, but does not modulate markers of inflammation.
Introduction
It has been well established that type 2 diabetes mellitus is associated with a decrease in the bioavailability of endothelium-derived nitric oxide (NO) and increased inflammation, which may explain the accelerated atherosclerosis in diabetes. [1] [2] [3] Increasingly, it has been realized that the endothelial dysfunction of diabetes may be partly related to oxidation of tetrahydrobiopterin, an essential co-factor for the endothelial NO synthase enzyme (eNOS), resulting in uncoupling of eNOS. [1] [2] [3] Uncoupled eNOS produces superoxide anions instead of NO, which can then inactivate NO and produce peroxynitrite. The loss of NO availability may contribute to inflammation through increased expression of the pro-inflammatory transcription factor nuclear factor kappa B, which then leads to upregulation of various chemokines and adhesion molecules. 4 As well, diabetes is associated with increased release of various pro-inflammatory adipokines that could contribute to vascular inflammation and atherogenesis. 5 Thus, modulating endothelial function and reducing inflammation may be important in diabetes to prevent atherosclerotic complications. [1] [2] [3] 6 We and others have demonstrated that folic acid can significantly improve endothelium-dependent vasodilation in patients with coronary artery disease, 7-10 asymptomatic hyperhomocysteinemia, 11, 12 and asymptomatic familial hypercholesterolemia. 13, 14 While this benefit may in part be related to homocysteinelowering, 7, 8 other studies suggest that the restoration of endothelial function by folates may be independent of its homocysteine-lowering effect. 10, 14 In fact, 5-methyltetrahydrofolate, the active metabolite of folic acid, may have direct effects on uncoupled eNOS, which results in increased release of NO and decreased release of superoxide anion. 13, 15, 16 Thus, there may be a rationale for considering the use of folates to restore NO availability in situations such as diabetes where there is a relative deficiency of active tetrahydrobiopterin. Indeed, van Etten et al 17 demonstrated that an acute arterial infusion of 5-methyltetrahydrofolate could restore impaired endothelium-dependent vasodilatation as assessed by forearm plethysmography in patients with type 2 diabetes. Additionally, it has been suggested that folic acid may potentially reduce levels of pro-inflammatory cytokines and may reduce inflammation, 18 although this has not been established in type 2 diabetes. 19 Accordingly, this study tested the hypothesis that short-term, high-dose folic acid supplementation could improve fasting endothelial dysfunction, as assessed by flow-mediated dilatation (FMD), and reduce levels of various circulating inflammatory markers in patients with type 2 diabetes, while only minimally reducing homocysteine levels.
Methods

Study population
Patients with recently diagnosed type 2 diabetes were screened from the Diabetes Management Centre and Heart Health Clinic at the Queen Elizabeth II Health Sciences Centre and from local advertisement. Patients between 35 and 65 years of age were eligible if they had confirmation of the diagnosis of type 2 diabetes on the basis of the Canadian Diabetes Association definition 20 and were controlled with diet alone to maintain a HbA1c Յ9%. Patients with any clinical evidence of cardiovascular disease (angina, myocardial infarction, stroke, transient ischemic attack, peripheral vascular disease, or uncontrolled hypertension (ie systolic BP Ͼ 180 mmHg; diastolic BP Ͼ 100 mmHg)) were excluded. To minimize any confounding effects on endothelium-dependent FMD and inflammatory markers, patients were excluded if they had any of the following: oral hypoglycemic agents or insulin use, total cholesterol Ͼ7 mmol/l or triglycerides Ͼ5 mmol/l, current smoking, or renal disease (creatinine Ͼ130 mol/l or proteinuria). Patients taking vitamin supplements (eg folic acid, vitamin B 12 , vitamin B 6 , vitamin C, vitamin E, ␤-carotene, or multivitamins) within 1 month of screening were also excluded. Twenty patients were enrolled to participate; one patient was unable to complete the protocol after 2 weeks because of personal matters. The study analysis was based on the 19 subjects who completed the protocol.
Study protocol
The study was a randomized, double-blind, placebocontrolled, cross-over trial comparing high-dose folic acid versus placebo. The protocol was approved by the Queen Elizabeth II Health Sciences Centre Research Ethics Committee and the study was conducted between May 2002 and March 2004. All patients gave written informed consent prior to any study procedures.
Patients were randomized to receive treatment with either oral folic acid (10 mg/day) for 2 weeks versus matching placebo capsules (one capsule/day) in a double-blind fashion. Randomization was performed according to a sealed envelope assignment. The dose of folic acid of 10 mg/day ϫ2 weeks was chosen, as this dose was shown to be effective in preventing lipidinduced decreases in FMD in healthy, non-diabetic volunteers and was felt to produce adequate 5-methyltetrahydrofolate levels. 21 Moreover, the short treatment duration was used to help minimize the effect of folic acid on homocysteine-lowering. At the end of 2 weeks of treatment, non-invasive endothelial function testing (FMD) was performed under fasting conditions. After an 8-week washout period, the patients were then crossed over to receive the alternate treatment (placebo vs. folic acid) for another 2 weeks. After the cross-over treatment was complete, a second FMD test was performed according to the same protocol used in the first study. Fasting blood samples for biochemical analysis were obtained prior to starting the first and second treatments and were repeated on the mornings of the endothelial function tests after each 2-week treatment. Whereas statins and angiotensin converting enzyme inhibitors are proven to improve FMD, these medications were kept at constant dosages, if used by the patient, but otherwise were not started during the 12-week study protocol. Patients and their referring physicians were instructed to avoid additional 'open-label' vitamin therapy during the 12-week study. The blood collections and endothelial function testing were always carried out after a 12-hour overnight fast. Long-acting vasoactive medications (angiotensin converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, beta-blockers, and nitrates) and folic acid study capsules were held for 24 hours before endothelial function testing. Compliance at the end of each 2-week treatment was assessed by pill count and was defined as taking greater than 80% of the study capsules.
Non-invasive assessment of endothelial function
Endothelium-dependent and endothelium-independent dilatation of the brachial artery was assessed noninvasively after each treatment using a high-resolution ultrasound system (Philips HDI 5000; Philips Medical Systems, Andover, MA, USA) with a 7-12 MHz lineararray vascular transducer, as previously described. 22, 23 Briefly, the brachial artery was imaged longitudinally, 2-15 cm above the antecubital crease. This location was recorded and reproduced on the repeat study. A pneumatic tourniquet, placed proximally on the forearm, was inflated to 250 mmHg pressure for 5 minutes and rapidly deflated, resulting in reactive hyperemia. Brachial artery images were obtained continuously for 30 seconds before cuff inflation (first baseline), at 50-110 seconds after cuff deflation (postreactive hyperemia), for another 30 seconds after 10 minutes of rest (second baseline), and for a further 60 seconds beginning 3 minutes after sublingual nitroglycerin (0.3 mg), and were recorded digitally.
Four end-diastolic frames (coincident with the peak of the electrocardiographic R-wave) were selected from the first baseline, second baseline, and postnitroglycerin (at 3 minutes following sublingual nitroglycerin administration) sequences. End-diastolic frames from three consecutive cardiac cycles were selected at 60, 70, 80 and 90 seconds after cuff release to assess the maximal FMD response after reactive hyperemia. Average end-diastolic brachial artery diameters were measured using commercially available, computer-assisted, brachial artery quantitative software (Dynamic Endothelial Assessment; Vasometrix, Calgary, Canada) by one observer, blinded to the patient's treatment assignment, as we previously described. 23 The coefficient of variation for repeat measurement of brachial artery diameter was 0.3%. Endothelium-dependent FMD was defined as the maximal percent change in brachial artery diameter (between 60 and 90 seconds) after reactive hyperemia compared to baseline. The intra-assay coefficient of variation for repeatedly measuring FMD in one subject was 1.9%. Endothelium-independent nitroglycerinmediated dilatation (NMD) was calculated as the percent change in brachial artery diameter at 3 minutes after nitroglycerin compared to the second baseline. Brachial artery flow and percent reactive hyperemia were calculated as previously described. 23 
Biochemical analyses
Venous blood was collected for the serial measurement of fasting levels of plasma glucose, total homocysteine, serum folate, lipids, and inflammatory markers (high-sensitivity C-reactive protein (hsCRP), soluble intercellular adhesion molecule-1 (sICAM-1) and vascular cell adhesion molecule-1 (sVCAM-1), interleukin-18 (IL-18), tumor necrosis factor-alpha (TNF-alpha)). Serum and plasma was separated immediately and frozen at Ϫ70°C for subsequent analysis. Plasma glucose and serum lipids were measured with a Beckman Synchron CX7 system (Beckman Coulter, Inc., Brea, CA, USA). Plasma total homocysteine and serum folate were measured using automated analyzers (Abbott IMx; Abbott Laboratories, Abbott Park, IL, USA and Roche Elecsys; Roche Diagnostics Corp., Indianapolis, IN, USA, respectively). Nephelometric assay was used to measure hsCRP levels (Dade-Behring, Inc., Deerfield, IL, USA). Levels of sICAM-1, sVCAM-1, IL-18, and TNF-alpha were measured with commercially available ELISA assays (R&D Systems, Minneapolis, MN, USA and MBL International, Woburn, MA, USA (for IL-18 only)).
Statistical analysis
First, we ruled out any carryover effect by looking for an interaction between the change in serum folate levels and the order in which patients received folic acid versus placebo, according to the Hills-Armitage method. 24 The primary endpoint, the effect of folic acid on endothelium-dependent FMD and endothelium-independent NMD, was assessed by comparing these measurements after folic acid versus placebo treatment, using one-way repeated measures analysis of variance (ANOVA). Secondary endpoints, the effects of folic acid on biochemical measures, were assessed by comparing the values pre-and posttreatment with folic acid versus placebo, using twoway repeated measures ANOVA. As the folate, homocysteine, and inflammatory marker values were skewed, a logarithmic transformation was performed and results are expressed as geometric means with 95% confidence intervals. Linear regression was used to assess the relationship between the change in FMD and changes in plasma homocysteine and serum folate. Our sample size of 20 was calculated in order to demonstrate an absolute 2.5% change in FMD (assuming standard deviation of 3% for the change in FMD) with folic acid treatment compared to placebo with 90% power (alpha ϭ 0.05; two-tailed test), while allowing for the potential drop out of two patients from the protocol. The study was not specifically powered for exploring the secondary effects on the inflammatory markers. Two-sided p-values less than 0.05 were considered to indicate statistical significance. Continuous data are expressed as mean Ϯ SD, unless stated otherwise.
Results
Characteristics of the patients
The study group consisted of 19 subjects (10 women, nine men) with type 2 diabetes, and the baseline clinical characteristics for the group are shown in Table 1 . The use of angiotensin converting enzyme inhibitors and lipid-lowering medications remained constant throughout the study period. The study drug was well tolerated and all patients were compliant with the two study treatments. The average compliance was 98% for folic acid and 97% for placebo. Figure 1 demonstrates the change in serum folate levels (geometric means) according to the treatment order of folic acid versus placebo. Those patients randomized to folic acid first had a fivefold increase in Folic acid improves diabetic endothelial function 103 folate levels at 2 weeks, which returned to the pretreatment level after the 8-week washout. In contrast, those who received folic acid following placebo, showed a similar fivefold increase in folate levels at 12 weeks, indicating that there was no order effect. Moreover, there was no interaction between the change in folate levels (pre-vs post-treatment) and the order in which the treatments were administered ( p ϭ 0.9), indicating there was no carryover effect. Pre-and post-treatment levels of total homocysteine, glucose, folate, and lipids are shown in Table 2 . Plasma homocysteine showed a modest 6% decrease from pretreatment levels following folic acid supplementation (p Ͻ 0.05 vs baseline); however, this was not significantly different than placebo ( p ϭ 0.3 by two-way ANOVA). Plasma glucose and serum lipid levels remained unaltered during folic acid and placebo treatments.
Effects on plasma total homocysteine, glucose, serum folate, and lipids
Effects on flow-mediated and nitroglycerinmediated dilatation
End-diastolic brachial artery diameters, brachial artery flow, percent reactive hyperemia, heart rate, and blood pressure were similar following folic acid and placebo treatment, as shown in Table 3 .
The effect of folic acid on endothelium-dependent FMD, the primary endpoint of the study, is shown for the overall group and individual patients in Figures 2 and 3 , respectively. Brachial artery FMD significantly increased following 2 weeks of folic acid supplementation compared with placebo (5.8 Ϯ 4.8% vs 3.2 Ϯ 2.7%; p ϭ 0.02 by one-way ANOVA; Figure 2A ). The improvement in FMD after folic acid treatment was similar in those who received folic acid versus. placebo treatment first ( Figure 2B ). While 15 patients showed improvement in FMD with folic acid, four patients did not respond (Figure 3 ). There were no predicting factors for responders versus. non-responders (eg baseline folate, homocysteine, brachial artery diameter, or FMD; change in folate or homocysteine; or compliance). Unlike FMD, endothelium-independent NMD remained unchanged following folic acid treatment compared with placebo (folic acid 18.2 Ϯ 4.4% vs placebo 17.8 Ϯ 4.8%; p ϭ 0.9). There was no significant correlation between the improvement in FMD and the change in plasma homocysteine (r ϭ 0.09; p ϭ 0.7) or the change in serum folate.
Effects on serum hsCRP, sICAM-1, sVCAM-1, IL-18, and TNF-alpha
Pretreatment and post-treatment levels of the inflammatory markers are shown in Table 4 . The baseline levels of the inflammatory markers were similar for folic acid versus placebo. The hsCRP levels tended to decrease following folic acid treatment compared to placebo, although this change was not significant (p ϭ 0.08 by-two-way ANOVA). The other inflammatory markers remained unchanged during folic acid and placebo treatments.
Discussion
Our study shows that 2 weeks of high-dose folic acid supplementation (10 mg/day) significantly increased endothelium-dependent FMD in patients with type 2 diabetes without vascular disease. This improvement in endothelial function appeared to be independent of the homocysteine-lowering effect of folates. On the other hand, folic acid treatment had no significant effect on endothelium-independent NMD, or serum inflammatory markers.
Oral folic acid supplementation has been shown to improve brachial artery endothelial function in subjects with hyperhomocysteinemia, 11, 12 familial hypercholesterolemia, 13, 14 and coronary artery disease. [7] [8] [9] [10] However, when we started our study, there was limited information in subjects with diabetes mellitus. Using forearm plethysmography, van Etten et al 17 demonstrated that subjects with type 2 diabetes have impaired endothelium-dependent, serotonin-induced vasodilation and mildly reduced endotheliumindependent vasodilation in response to sodium nitroprusside. Acute intra-arterial administration of 5-methyltetrahydrofolate, the active metabolite of folic acid, restored the endothelium-dependent vasodilation, but had no effect on endothelium-independent vasodilation in these subjects. Since then, Pena et al 25 studied the effect of 8 weeks of oral folic acid (5 mg/day) on brachial artery FMD in a randomized, double-blind, cross-over study in children and adolescents with type 1 diabetes. Although their study was limited by a carryover effect on serum folate due to insufficient washout, they were still able to demonstrate an absolute 2.58% increase in FMD with folic acid, with no effect on NMD. More recently, Mangoni et al 26 demonstrated that 4 weeks of folic acid (5 mg/day) could improve endothelium-dependent acetylcholine-induced forearm blood flow, as measured by venous plethysmography, but had no effect on endothelium-independent vasodilation in 26 patients with type 2 diabetes without vascular disease. Our results are in agreement with these recent studies, and extend the findings to patients with type 2 diabetes, showing significant improvement in endothelial function, as assessed by FMD, with only 2 weeks of highdose supplementation. There is limited information on the benefits of folates in reducing inflammation, especially in diabetes. Holven et al 18 demonstrated that short-term folic acid supplementation could reduce the oxidized low-density lipoprotein-stimulated release of various chemokines in peripheral blood mononuclear cells isolated from nondiabetic subjects with hyperhomocysteinemia. Similar to our study, they found that folic acid did not reduce circulating levels of these chemokines. More recently, Spoelstra-de et al 19 specifically tested the effect of folic acid (5 mg/day) on circulating levels of various inflammatory markers (hsCRP, soluble adhesion molecules, interleukin-6, and TNF-alpha) in patients with type 2 diabetes and, similarly to our study, found no effect on any of these biomarkers. Importantly, our study cannot rule out an anti-inflammatory effect at the cellular level, as we only measured circulating markers.
The mechanism by which folic acid supplementation may improve endothelium-dependent vasodilation in type 2 diabetes remains speculative. While previous studies have suggested that the benefits of folic acid on FMD are partly dependent on its homocysteine-lowering effect, 7,8 our present study suggests the effects are independent of homocysteine-lowering, confirming the findings of the other recent diabetic studies. 25, 26 It has been realized that the oxidative stress of diabetes may lead to oxidation of tetrahydrobiopterin, an essential co-factor of eNOS, resulting in the uncoupling of the eNOS enzyme and a loss of NO availability. 16 Of relevance to our findings, in vitro studies have demonstrated that 5-methyltetrahydrofolate can have direct effects on uncoupled eNOS, where it can increase the production of NO and reduce the release of superoxide anions in a tetrahydrobiopterindependent manner. 16 This is further supported by two human studies whereby the acute intra-arterial administration of 5-methyltetrahydrofolate restored endothelial function in patients with familial hypercholesterolemia 13 and type 2 diabetics, 17 without lowering plasma homocysteine Thus, it is plausible that folic acid may restore endothelial function in diabetes, independent of homocysteine. There are a number of theoretical mechanisms by which folates may restore uncoupled eNOS back to a NO-producing enzyme. First, folates may increase the availability of tetrahydrobiopterin by stimulating the regeneration of tetrahydrobiopterin from the oxidized, inactive form of dihydrobiopterin. Alternatively, the direct antioxidant effects of folic acid may stabilize tetrahydrobiopterin and prevent its oxidation. 16 Additionally, folates may facilitate the binding of tetrahydrobiopterin to eNOS. 15, 16 Finally, it has been speculated that 5-methyltetrahydrofolate may mimic tetrahydrobiopterin at its receptor site on eNOS or may facilitate the electron transfer to produce NO. 15, 27 There are certain limitations to our study. First, our study only looked at the effect of folic acid on surrogate endpoints (FMD and inflammatory markers) in a relatively small number of diabetic subjects. Our FMD results demonstrate considerable inter-patient variation of FMD with a wide range of values noted with folic acid and placebo, which is similar to that seen in other studies which have used similar methodology. 7, 8, 21, 23, 25, [28] [29] [30] Despite this variability, our study was sufficiently powered to demonstrate the absolute 2.6% increase in FMD with as few as 18 patients in this cross-over design. 31, 32 On the other hand, as our study was only powered according to the effect on FMD, this small sample size may have been insufficient to demonstrate a significant secondary effect on the inflammatory markers. Finally, had we used a longer treatment duration, it is possible we may have seen a greater reduction in homocysteine levels, which may have produced a relationship between the change in homocysteine and FMD.
In summary, we have shown that folic acid supplementation can improve endothelial dysfunction in subjects with type 2 diabetes without vascular disease, independent of lowering plasma homocysteine. Given the importance of endothelial dysfunction in the accelerated atherogenesis of diabetes, these results provide a rationale for studying whether folates may help prevent cardiovascular complications in diabetes. However, we must await the results from various large-scale, longterm clinical trials of folic acid (e.g. HOPE-2 study which includes a large number of diabetic patients), before recommending routine folic acid supplementation in patients with type 2 diabetes. 33 
